CAPhO Conference 2023

Program

The Conference program is developed around a theme and will feature a diverse slate of plenary, concurrent sessions and round table discussions to engage and inform participants of the advances in oncology pharmacy. New this year is the Bone Marrow Transplant (BMT 101) Workshop taking place on Thursday, April 13. 

In addition to leading-edge education, the program will include two opportunities to interact with CAPhO’s leadership during CAPhO’s Annual General and Town Hall Breakfast meetings – your chance to discuss relevant questions affecting the association. And, as always, there will be a number of sponsored symposia taking place as well as networking events with the Welcome Reception on Friday and the CAPhO Awards Gala on Saturday evenings. 

The program will be accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP). 

Click here to download the Program at a Glance.

Download a copy of the Abstract Book.

Monday
April 10, 2023
Program is subject to change. All times indicated are Eastern Daylight Times (EDT).

On-demand symposia
Merck & AstraZeneca On-Demand Symposium

Treatment Evolutions & Approaches in the Management of Prostate Cancer: Bridging the Gap between Science and Patients

Learning objectives:

At the conclusion of this program, participants should be able to:

  1. Recognize the DNA damage response (DDR) gene mutations that are involved in prostate cancer, and their implications for therapy
  2. Integrate genetic testing for patients with prostate cancer into their clinical practice
  3. Describe the mechanism of action, efficacy, and safety of PARP inhibitors in order to employ these agents for the treatment of prostate cancer with DDR mutations
  4. Explain the timing, monitoring, and management of adverse events
On-demand symposia
Amgen On-Demand Symposium
Presenters
Mova Leung
Glenn Myers
Photo of Mova Leung
Photo of Mova Leung
Mova Leung
Oncology Pharmacy Practitioner, Oncology, North York General Hospital — North York, Ontario
Mova is the Oncology Clinical Pharmacy Practitioner at North York General Hospital. She leads and promotes the clinical activities of the oncology pharmacy team, and drug utilization for the Cancer Care program. She is also Course Coordinator and Adjunct Lecturer of the Hematology, Oncology and Immunotherapy course at the University of Toronto’s Faculty of Pharmacy. Mova Leung graduated from the University of Toronto with her BSCPhm, then a PharmD and subsequently completed a Pharmacy Practice residency. She also holds her Board Certification in Oncology. She is the Oncology Clinical Pharmacy Practitioner at North York General Hospital and Adjunct Lecturer at the University of Toronto’s Faculty of Pharmacy. At NYGH, she leads and promotes the clinical activities of the oncology pharmacy team, drug utilization, and drug access navigation for the Cancer Care program. Working closely with oncologists and hematologists, the Allied Health team, and Palliative Care, she strives to optimize patient care. At the Faculty of Pharmacy, Mova is course coordinator and lecturer for the Oncology, Hematology and Immunology course. Her other professional activities include precepting, publishing, research and involvement in institutional, regional, and national oncology committees.
Mova Leung
North York General Hospital, North York, Ontario
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
Pharmacist with clinical focus in outpatient medical oncology, Dr. Sheldon H Rubin Oncology Clinic — Moncton, New Brunswick

Glenn Myers completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy. 

Glenn Myers
Dr. Sheldon H Rubin Oncology Clinic, Moncton, New Brunswick

The Amgen pre recorded symposium will cover two topics for 30 minutes each.

Topic #1: Practical Solutions to managing EGFR inhibitor related adverse events in patients with metastatic colorectal cancer 


Presentation Summary:

Description: Monoclonal Antibody EGFR inhibitors play an important role in the 1L treatment of RAS Wild-type metastatic colorectal cancer (mCRC) patients. This class of drug is associated with a set of unique but predictable dermatologic and renal toxicities. This video will review the role of EGFR inhibitors in the management of mCRC and the most common side effects to expect during treatment. The video will also review the important role Pharmacists play in both proactive and reactive strategies to optimize the management of EGFRi related toxicities.

Topic #2: A Rapid Review of Bone Targeted Agents (BTAs) and the role of Pharmacy in Optimizing Patient Care


Presentation Summary: 

Bone is a frequent site of metastatic disease for solid tumors and multiple myeloma. Untreated bone metastases can result in skeletal related events (SREs) such as pathologic fractures, spinal cord compression, hypercalcemia, and uncontrolled pain. Bone targeted agents (BTAs) can delay time to first and subsequent SREs, correct hypercalcemia, and improve pain control. Pharmacists can play a key role through patient education, subcutaneous dose administration, dose optimization, ensuring adherence to toxicity preventative strategies, and collaborative toxicity management. This session will provide an overview of BTAs, their associated toxicity, and how pharmacists can play a key role in the patient journey.

On-demand symposia
BeiGene On-Demand Symposium
Presenters
Anthony J Perissinotti
Anthony J Perissinotti
Clinical Pharmacist Specialist, Hematology, Adjunct Clinical Assistant Professor, University of Michigan - Michigan Medicine
Anthony J Perissinotti
University of Michigan - Michigan Medicine

Integrating Pharmacists into Multidisciplinary Decisions for Patients with CLL: The Pharmacist’s Toolkit for Pushing Practice Forward

This symposium provides a review of current targeted treatment options in CLL and key supporting clinical data focused on practical perspectives to pharmacists. The presentation highlights differentiated MOA and DDI’s of agents and practical management of adverse events. The objective is help increase pharmacist’s confidence in the multidisciplinary management of CLL patients in an era of many new developments and new clinical data.

Thursday
April 13, 2023
Program is subject to change. All times indicated are Eastern Daylight Times (EDT).

Bone Marrow Transplant (BMT 101) Workshop- Sponsored by Jazz Pharmaceuticals

The Bone Marrow Transplant (BMT 101) Workshop is an in-person workshop developed by the Education Pharmacist Advanced Committee and sponsored by Jazz Pharmaceuticals. A limited number of seats are available so register now to ensure you reserve your spot. 

Learning objectives:

  1. Describe the different types of cellular therapy used to treat hematologic malignancies
  2. Identify early and late complications following hematopoietic stem cell transplant
  3. Describe the role of a pharmacist in caring for patients who have received a stem cell transplant
  4. Identify drug related problems and develop a supportive care plan for patients undergoing cellular therapy
Registration
Registration Open
Satellite symposium
Apotex Sponsored Symposium- Evolution in Multiple Myeloma (MM) – Past, Present and Future
Presenters
Neil Berinstein
Carmilia Sun
Susan Singh
Photo of Neil Berinstein
Photo of Neil Berinstein
Neil Berinstein
Hematologist, Sunnybrook Hospital

Dr. Neil Berinstein (MD, FRCPC, ABIM) is a Hematologist and Affiliate Scientist at the Odette Cancer Centre at Sunnybrook Hospital in Toronto, ON and a Professor of Medicine at the University of Toronto. He completed his Medical Degree at the University of Manitoba (1978), as well as fellowships in both Internal Medicine (1982) and Medical Oncology (1984) from the Royal College of Physicians of Canada, followed by a Postdoctoral research fellowship at Stanford University (1988). Dr. Berinstein's research focuses on novel approaches to treat hematologic malignancy including combination immunotherapy and new targeted agents. He has led several multicentre translational clinical trials looking at novel therapeutics and identification of novel biomarkers.

Neil Berinstein
Sunnybrook Hospital
Photo of Carmilia Sun
Photo of Carmilia Sun
Carmilia Sun
Oncology Pharmacist, Sunnybrook Hospital Pharmacy

Carmilia Sun is a clinical pharmacist at the Sunnybrook Odette Cancer Centre. She completed her pharmacy education at the University of Waterloo in 2015, then proceeded to complete an Accredited Canadian Pharmacy Residency at Sunnybrook in 2016, and has been working at the Odette Centre Pharmacy ever since. She is experienced in chemotherapy order review, symptom management, and regimen building. She is also a member of the centre’s Oral Anticancer Medication (OACM) Team and led the program from 2021-2022, integrating several new oral agents into the follow-up program and spearheading the changeover to various generic products. The team works closely with oncologists, nurses, and drug access navigators to provide the best education & proactive monitoring to patients on oral chemotherapy treatments. Carmilia is a co-author of numerous posters at CAPhO Conference this year, so feel free to visit her and the OACM Team at the exhibits this weekend!

Carmilia Sun
Sunnybrook Hospital Pharmacy
Susan Singh
Pharmacy Technician, Sunnybrook Hospital Pharmacy
Susan Singh
Sunnybrook Hospital Pharmacy

Join Apotex for a live 90 minute symposium exploring the Evolution of Multiple Myeloma – past, present and future. This symposium will be presented from the unique perspective of three members of Sunnybrook Hospital’s multi-disciplinary myeloma patient management team, including Dr. Neil Berinstein (hematologist), Carmilia Sun (oncology pharmacist) and Susan Singh (pharmacy technician).  Dr. Berinstein will highlight the clinical and therapeutic evolution of the treatment of multiple myeloma, followed by Carmilia Sun who will touch on the financial impact of myeloma treatment and the need for sustainability within the Canadian healthcare system. Lastly, Susan Singh will close the symposium discussing the increasingly important role of pharmacy in patient management and support in the management of multiple myeloma. 

Learning Objectives:

  1. To understand Multiple Myeloma (MM) and how treatment has evolved and continues to evolve.
  2. To understand the impact of the cost of treating MM on the healthcare system and role generics can play in sustainability. 
  3. To understand the important and evolving role of the pharmacist in patient care and support.
Satellite symposium
IPSEN Sponsored Symposium- Ask the Experts – The Role of the Oncology Pharmacist within the Multi-Disciplinary Team on Optimizing Patient Experience on Oral VEGF Inhibitors
Presenters
Scott Edwards
Joy McCarthy
Glenn Myers
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — St John's, Newfoundland and Labrador
Scott Edwards is currently the Clinical Oncology Pharmacy Specialist at the Dr. H. Bliss Murphy Cancer Center in St. John’s, Newfoundland. He is also an assistant professor at the School of Pharmacy and the Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland. He is active in clinical cancer research in the area of chemotherapy toxicities, supportive care and oral chemotherapy adherence. He graduated from Memorial University of Newfoundland with a B.Sc. (Neuroscience) in 1994 and a B.Sc (Pharmacy) in 1997. In 2005, he graduated with a Doctor of Pharmacy degree from the University of Washington. He completed a Master’s degree in Oncology from Newcastle University in 2015.
Scott Edwards
Eastern Health, St John's, Newfoundland and Labrador
Photo of Joy McCarthy
Photo of Joy McCarthy
Joy McCarthy
Medical Oncologist and Division Chief of Medical Oncology , Cancer Care Program , Eastern Health — St John's, Newfoundland and Labrador

Dr. Joy McCarthy is a Medical Oncologist and Division Chief of Medical Oncology with the Cancer Care Program of Eastern Health in St. John’s, NL.  She is a Clinical Associate Professor within the Discipline of Oncology, Memorial University of Newfoundland.  Dr. McCarthy completed her Medical Degree at Memorial University of Newfoundland in 1996 and her certifications in Internal Medicine in 2000 and Medical Oncology in 2001.  Dr. McCarthy is a member of the Beatrice Hunter Cancer Research Institute, CAMO, ASCO, CCTG, Cancer Care Program’s Leadership Team and Clinical Trials Committee.  Her areas of interest include breast, genitourinary and head and neck cancer.  She is a busy mom of three and an avid runner.

Joy McCarthy
Eastern Health , St John's, Newfoundland and Labrador
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
Dr. Sheldon H Rubin Oncology Clinic, Pharmacist with clinical focus in outpatient medical oncology — Moncton, New Brunswick

Glenn Myers completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy. 

Glenn Myers
Pharmacist with clinical focus in outpatient medical oncology, Moncton, New Brunswick

Presentation Summary:

A moderated panel including medical oncology and oncology pharmacy experts who will discuss the critical collaboration of the oncology pharmacist within the multi-disciplinary team, to support and manage patients with advanced renal cell carcinoma (aRCC) throughout their treatment journey.  The session will outline the utilization of oral VEGF inhibitors for the treatment of aRCC, including the mechanism of action and common adverse events.  The panel will explore best practices for monitoring and managing oral VEGF inhibitors, including patient counseling & AE management, as well as discuss strategies for collaborating across the multi-disciplinary team to facilitate positive patient experience and optimize therapy. These best practices can extend beyond application for aRCC to other disease sites where oral VEGF inhibitors are indicated.


Learning Objectives: 

  1. Describe the role of oral VEGF (TKI) inhibitors in the treatment of advanced renal cell carcinoma (aRCC)  
  2. Identify best practices for monitoring and managing oral VEGF inhibitors as single agents and in combination with immunotherapy
  3. Discuss multi-disciplinary team strategies to optimize therapy and patient experience with oral VEGF inhibitors

Friday
April 14, 2023
Program is subject to change. All times indicated are Eastern Daylight Times (EDT).

Registration
Registration Open
Satellite symposium
Servier Sponsored Symposium - Therapeutic Drug Monitoring: Its utility and application in Optimizing Asparaginase therapy in ALL
Presenters
Dr. Bernard L. Marini
Photo of Dr. Bernard L. Marini
Photo of Dr. Bernard L. Marini
Dr. Bernard L. Marini
PharmD, BCOP
Clinical Pharmacist specialist in Hematology, Clinical Associate Professor, University of Michigan College of Pharmacy — Ann Arbor, Michigan

Bernard Marini, PharmD, BCOP is a Clinical Pharmacist specialist in Hematology and Clinical Associate Professor at the University of Michigan College of Pharmacy. He completed Pharmacy School, a PGY1 Pharmacy Practice Residency, and a PGY2 Hematology/Oncology Pharmacy at the University of Michigan, thereafter taking a position as the inpatient hematology clinical pharmacist at U of M in 2014. Dr. Marini is an expert in the treatment of acute leukemias and serves as a vital member of the leukemia tumor board and leukemia research group at Michigan Medicine. Dr. Marini is heavily involved in research aiming to improve outcomes in acute leukemia patients and has over 75 peer-reviewed publications. In his spare time, he enjoys coaching his two daughters’ hockey and lacrosse teams, brewing average beer, and doing his worst Auston Matthews impression on the ice for his local hockey team. 

Dr. Bernard L. Marini
University of Michigan College of Pharmacy, Ann Arbor, Michigan

Presentation Summary

Asparaginase is a cornerstone of Acute Lymphoblastic Leukemia (ALL) chemotherapy treatment. Despite its use for more than 40 years, the administration of asparaginase does come with its challenges. Toxicities, such as hypersensitivity, of asparaginase are well documented, yet remain an issue and it is important to understand how to manage them. Experience and clinical studies have shown us that not receiving all prescribed asparaginase doses was associated with inferior outcomes.

Learning Objectives

  1. Review the management of hypersensitivity reactions; rechallenge, desensitize, or switch. 
  2. Lessons learned from the University of Michigan experience in times of drug availability volatility.
  3. Understand the application and value of Therapeutic Drug Monitoring (TDM) to ensure efficient utilization of Asparaginase options. 
  4. Discuss future treatment options for Asparaginase therapy in ALL.
Satellite symposium
Seagen Sponsored Symposium- Practical Approaches to Supporting Patients with New Therapies in HER2+ mBC and mUC
Presenters
Jennifer Daley-Morris
Kirollos S. Hanna
Photo of Jennifer Daley-Morris
Photo of Jennifer Daley-Morris
Jennifer Daley-Morris
Manager of the Oncology Pharmacy and Systemic Therapy Suite, Stronach Regional Cancer Centre, Southlake Health — Newmarket, Ontario
Jennifer Daley-Morris
Stronach Regional Cancer Centre, Southlake Health , Newmarket, Ontario
Photo of Kirollos S. Hanna
Photo of Kirollos S. Hanna
Kirollos S. Hanna
Director of Pharmacy, Assistant Professor, Minnesota Oncology, Mayo Clinic Care Network
Kirollos S. Hanna
Mayo Clinic Care Network

Presentation Summary
HER2+ metastatic breast cancer (mBC) therapy options have been evolving rapidly. This symposium will review new therapies for HER2+ mBC, the updated CADTH funding algorithm, and provide practical suggestions to managing adverse events especially for patients taking multi-drug regimens.

The metastatic urothelial cancer (mUC) treatment landscape has also seen new therapies come to market. Join us for a review of recent therapy options and discuss approaches to patient counselling and management of treatment-emergent adverse events. 


Learning Objectives:

  1. Review the treatment landscape for HER2+ mBC patients and access to new therapies
  2. Discuss challenges of counselling patients with multi-drug regimens and share best practices 
  3. Understand current approaches to patient counselling in the treatment landscape for mUC
  4. Implementation of management strategies to prevent or alleviate treatment-emergent adverse events from newer mUC therapies
Satellite symposium
FORUS Therapeutics Sponsored Symposium- Making Sense of the Evolving Treatment Landscape in Early Relapsed and Refractory Multiple Myeloma (rrMM)
Presenters
Peter Anglin
Jonathan Stevens
Jennifer Daley-Morris
Dominic Duquette
Photo of Peter Anglin
Photo of Peter Anglin
Peter Anglin
MD, FRCPC, MBA
Hematologist/Medical Oncologist and Physician Lead , Stronach Regional Cancer Centre, Southlake Health — Newmarket, Ontario
Peter Anglin
Stronach Regional Cancer Centre, Southlake Health, Newmarket, Ontario
Photo of Jonathan Stevens
Photo of Jonathan Stevens
Jonathan Stevens
B.Pharm, ACPR
Clinical pharmacist in hematology , Saint John Regional Hospital — Saint John, New Brunswick
Jonathan Stevens
Saint John Regional Hospital, Saint John, New Brunswick
Photo of Jennifer Daley-Morris
Photo of Jennifer Daley-Morris
Jennifer Daley-Morris
RPh, B.Pharm
Manager of the Oncology Pharmacy and Systemic Therapy Suite, Stronach Regional Cancer Centre, Southlake Health — Newmarket, Ontario
Jennifer Daley-Morris
Stronach Regional Cancer Centre, Southlake Health, Newmarket, Ontario
Photo of Dominic Duquette
Photo of Dominic Duquette
Dominic Duquette
B.Pharm, M.Sc.
Clinical Pharmacist, CHU de Québec — Québec, Quebec
Dominic Duquette
CHU de Québec, Québec, Quebec

Presentation Summary 
Recent advancements in the treatment of multiple myeloma (MM) include the addition of novel therapeutics, combination strategies and moving these novel combinations into the front line setting for patients living with MM.  Despite these advancements, MM remains an incurable disease and patients will require multiple lines of therapy. 
Treatment strategies for early rrMM can be confounded by many factors including prior therapies, response to prior therapies, disease biology, underlying comorbidities, and patient choice.  
This symposium is intended to strengthen the oncology/hematology pharmacists’ understanding of the evolving treatment landscape in early rrMM and, through a collaborative approach with a multidisciplinary team, how to improve patient outcomes and experiences throughout their myeloma journey.   

Learning Objectives
At the end of the symposium, pharmacist participants should be better able to:

  1. Identify the evolving unmet needs for patients with early rrMM
  2. Describe factors that influence sequencing in early MM, including the current recommendations based on available CADTH Provisional Algorithm
  3. Compare and contrast the treatment options available for patients progressing on daratumumab
  4. Implement strategies through collaboration with a multidisciplinary care team for optimal management of adverse events with novel therapies for early rrMM 
Satellite symposium
Novartis Sponsored Symposium- Management of HR+ HER2- Advanced Breast Cancer- A Case-Based Panel Discussion for Pharmacists
Presenters
Thomas McFarlane
Dr. Katarzyna Jerzak
Scott Edwards
Photo of Thomas McFarlane
Photo of Thomas McFarlane
Thomas McFarlane
Clinical Lecturer/Researcher, Pharmacy, University of Waterloo — Kitchener, Ontario
Tom is currently a Clinical Lecturer and a researcher at the University of Waterloo School of Pharmacy in Kitchener, Ontario, where he created, coordinates, and teaches the oncology portion of the curriculum in the Doctor of Pharmacy program and conducts practice based research.
Thomas McFarlane
University of Waterloo, Kitchener, Ontario
Photo of Dr. Katarzyna Jerzak
Photo of Dr. Katarzyna Jerzak
Dr. Katarzyna Jerzak
Medical Oncologist and Clinician Investigator, Sunnybrook Odette Cancer Center — Toronto, Ontario

Dr. Katarzyna Jerzak completed medical school and internal medicine residency training at McMaster University. Then, she pursued medical oncology sub-specialty training at the University of Toronto (2013-2015) where she was the co-Chief Medical Resident. Dr. Jerzak completed medical oncology fellowship training at the Sunnybrook Odette Cancer Centre, and obtained an MSc degree in Clinical Epidemiology at the University of Toronto. Among other awards and grants, she was a recipient of the prestigious Conquer Cancer of ASCO Career Development Award in 2019. Dr. Jerzak is a Medical Oncologist and Clinician Investigator at the Sunnybrook Odette Cancer Center and Assistant Professor at the University of Toronto with a clinical focus on breast cancer. She is the lead of breast oncology clinical trials at her Centre and a member of the NRG Oncology Breast Cancer Committee. 

Dr. Katarzyna Jerzak
Sunnybrook Odette Cancer Center, Toronto, Ontario
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — St John's, Newfoundland and Labrador
Scott Edwards is currently the Clinical Oncology Pharmacy Specialist at the Dr. H. Bliss Murphy Cancer Center in St. John’s, Newfoundland. He is also an assistant professor at the School of Pharmacy and the Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland. He is active in clinical cancer research in the area of chemotherapy toxicities, supportive care and oral chemotherapy adherence. He graduated from Memorial University of Newfoundland with a B.Sc. (Neuroscience) in 1994 and a B.Sc (Pharmacy) in 1997. In 2005, he graduated with a Doctor of Pharmacy degree from the University of Washington. He completed a Master’s degree in Oncology from Newcastle University in 2015.
Scott Edwards
Eastern Health, St John's, Newfoundland and Labrador

In HR+ HER2- advanced breast cancer, the pharmacist is a key member of the multi-disciplinary health care team and an important resource in the patient journey. Given the rapidly evolving science, and maturation of clinical trial data, the ability to remain up to date can be challenging.”
Our distinguished faculty have put together case-based scenarios to initiate discussion and provide up to date information for treatment decision making as well as therapeutic monitoring and management”
Please join us on Friday, April 14, 2023, from 12:15 to 13:45 pm EDT.
 

Satellite symposium
Apobiologix Sponsored Symposium- Retention Strategies to Address the Post Pandemic Human Resource Crisis in Healthcare and Apobiologix HOPE Awards
Presenters
Raelynn Douglas
Nirmesh Shah
Photo of Raelynn Douglas
Photo of Raelynn Douglas
Raelynn Douglas
Chief Executive Officer, Raesoleil Consulting

Raelynn Douglas is the CEO of Raesoleil Consulting, a consulting company that focusses on building resilience in individuals and teams. Her programs train leaders in unique competencies that can be a differentiator in their career development; enabling leadership teams to make the smartest investments with high return on their investment and allowing organizations to thrive, innovate and grow. Her programs are designed for maximum impact, that can be scaled efficiently across organizations, so we retain our important workforce, and save scarce resources.
Raelynn’s career started in the Saskatchewan Ministry of Finance, where she led teams in budget analysis, strategic planning, performance management, program evaluation and transformational change. Working in the Ontario healthcare sector from 2012-2022, she developed expertise in service provider relations, innovation, digital health, and ignited a deep passion for the health human resource (HHR) shortage. This curiosity led her to pursue an MBA with a specific focus on the HHR crisis, and to design a consulting company with the specific intent - to help organizations create great cultures where people love to work. She returned to her home province of Saskatchewan in the summer of 2022 to take on the role of Executive Director, Drug Plan in the Ministry of Health and is excited to be applying her leadership skills to this important part of our health care system.
Raelynn has a BA in Economics from the University of Saskatchewan and a Global MBA in Health and Life Sciences from the Rotman School of Business, University of Toronto. She is a member of the Canadian College of Health Leaders (CCHL) and earned her Certified Health Executive (CHE) designation in 2020. Raelynn is also a Facilitator with CCHL and with the National Institutes of Health Informatics. She serves on the Board of Resilient Kids Canada and is the Vice President, Membership for Guelph Public Speakers, an accomplished Toastmasters club.

Raelynn Douglas
Raesoleil Consulting
Photo of Nirmesh Shah
Photo of Nirmesh Shah
Nirmesh Shah
PharmD
Vice President, Medical Affairs, Apobiologix

Nirmesh has over 15 years of experience in the pharmaceutical industry working in both the commercial and medical affairs divisions. He has been with Apotex since 2015 and he previously worked for IQVIA as the Director of Medical Affairs. Nirmesh has also worked for Johnson & Johnson and Sunovion. He received his Doctor of Pharmacy at the University of South Carolina.

Nirmesh Shah
Apobiologix

Presentation Summary:

Part 1 of this year’s Apobiologix Symposium will discuss the important topic of retention strategies to address the post pandemic human resource crisis in healthcare. Raelynn Douglas, the Executive Director of the Saskatchewan Drug Plan, will discuss the current healthcare human resource crisis and its high cost. She will also define the retention strategies you can employ to reverse this trend, and describe what actions individuals and leaders should be taking to address these challenges.
Part 2 of the Symposium will include the announcement of the annual HOPE Award winners, as well as their presentations.  

Satellite symposium
EMD Serono and Pfizer Canada Sponsored Symposium- UC Patient NOW: Applying a Patient-centred Approach to the Use of Maintenance Immunotherapy for the First-line Treatment of Advanced or Metastatic Urothelial Carcinoma (aUC)
Presenters
Glenn Myers
Dr. Bernhard Eigl
Michelle Forman
Dennis Hovorka
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
Pharmacist with clinical focus in outpatient medical oncology, Dr. Sheldon H Rubin Oncology Clinic — Moncton, New Brunswick

Glenn Myers completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy. 

Glenn Myers
Dr. Sheldon H Rubin Oncology Clinic, Moncton, New Brunswick
Photo of Dr. Bernhard Eigl
Photo of Dr. Bernhard Eigl
Dr. Bernhard Eigl
MD, FRCPC
Medical Oncologist, BC Cancer Agency — Vancouver, British Columbia

Dr. Eigl is a staff medical oncologist at the Vancouver Cancer Centre and Clinical Associate Professor at the University of British Columbia.  He is the Medical Lead of the Vancouver Centre Clinical Trials Unit.  He is also the Director of the Provincial Clinical Trials Office. The focus of this role is to strengthen and further develop the clinical trial capabilities of all six cancer centers in BC and to improve access to clinical trials for those living with cancer. His clinical areas of expertise are in genitourinary oncology and clinical trials, with a special focus in bladder and prostate cancers where he has held national and international leadership positions on several clinical trials.  

Dr. Bernhard Eigl
BC Cancer Agency, Vancouver, British Columbia
Photo of Michelle Forman
Photo of Michelle Forman
Michelle Forman
RN, CON(c)
Oncology Nurse, Burnaby Hospital Cancer Centre — Burnaby, British Columbia

Michelle Forman has been working in the outpatient oncology clinic at Burnaby Hospital since 1995, and prior to that had worked in various areas throughout the hospital. Her current role includes administering chemotherapy, patient teaching and management of disease symptoms and treatment side effects. Michelle is passionate about oncology nursing and feels that her knowledge and experience play an integral role in helping to provide for the physical and emotional patient care needs. Michelle has also enjoyed the opportunity to be involved in many projects aiming to enhance the cancer patients experience as well as educating fellow oncology nurses.

Michelle Forman
Burnaby Hospital Cancer Centre, Burnaby, British Columbia
Photo of Dennis Hovorka
Photo of Dennis Hovorka
Dennis Hovorka
Patient living with advanced bladder cancer — Vancouver, British Columbia

Dennis is a retired public school principal and financial planner. He lives in Vancouver with his partner, Claire, and has two children and five grandchildren. First diagnosed with bladder cancer in 2017, Dennis is now under the care of a team at BC Cancer. He is a member of local bladder cancer support group and is motivated to share his personal journey with others.

Dennis Hovorka
Patient living with advanced bladder cancer, Vancouver, British Columbia

Presentation Summary: 

Although recent guidelines and clinical evidence support the use of first-line maintenance immunotherapy as the new standard of care for eligible aUC patients, pharmacists are still learning how to effectively integrate this therapeutic approach into clinical practice. Highlighted by a real patient who will share their personal journey living with aUC, this program will use a patient-centred approach to build on the foundational knowledge established during the 2022 "UC NOW" program. The experienced speakers will share their personal experience and discuss how the latest evidence can be applied to complex patient scenarios. 

Learning Objectives: 

  1. Translate the current evidence for first-line maintenance immunotherapy into clinical scenarios that can be applied in practice.   
  2. Formulate strategies to enhance the care of complex patients receiving maintenance immunotherapy.   
  3. Optimize shared decision making and patient education to effectively address unmet needs throughout the aUC journey.  
Satellite symposium
AstraZeneca Sponsored Symposium-The Power of Oncology Pharmacists to Improve Adherence and Optimize Patient Outcomes with Oral Oncology Medications
Presenters
Jonathan Stevens
Anna Granic
Photo of Jonathan Stevens
Photo of Jonathan Stevens
Jonathan Stevens
BScPharm, ACPR
Interim Clinical Pharmacy Manager, Pharmacy, Horizon Health Network, Saint John Regional Hospital — Quispamsis, New Brunswick
Jonathan Stevens
Horizon Health Network, Saint John Regional Hospital, Quispamsis, New Brunswick
Photo of Anna Granic
Photo of Anna Granic
Anna Granic
Pharmacy Coordinator, Pharmacy, Grand River Regional Cancer Centre — Waterloo, Ontario
Anna has been a pharmacist at Grand River Hospital for over 30 years and has worked in the Oncology program for over 20 years. She is the regional systemic pharmacy lead for the oncology program, and participates in the continuing education of both nursing and pharmacy staff in the region when new drugs and regimen are approved for use and funded. Currently, Anna is also part of the build team as the Cancer program transitions to a new CPOE system in the near future.
Anna Granic
Grand River Regional Cancer Centre, Waterloo, Ontario

Presentation Summary: 

Join us for a live 90-minute symposium exploring the power of oncology pharmacists to improve adherence and optimize patient outcomes with oral oncology medications, such as BTK inhibitors for the management of chronic lymphocytic leukemia (CLL).

Learning Objectives:

  1. Elevate the impact of the Oncology Pharmacy Team to empower patients via education on the optimal use of oral oncology medications 
  2. Understand the importance of patient adherence and persistence in the context of oral BTK-inhibitors and chronic lymphocytic leukemia (CLL) 
  3. Implement pharmacy best practices to drive short-term and long-term patient adherence to oral BTK-inhibitors 
Networking session
Welcome Reception- Exhibits and Posters Viewing

Saturday
April 15, 2023
Program is subject to change. All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Takeda Sponsored Symposium - Applied Artificial Intelligence in Healthcare: Implications for Clinical Pharmacists in Oncology
Presenters
Dr. Muhammad Mamdani
Photo of Dr. Muhammad Mamdani
Photo of Dr. Muhammad Mamdani
Dr. Muhammad Mamdani
Vice President – Data Science and Advanced Analytics at Unity Health Toronto, Odette Chair in Advanced Analytics, Faculty Affiliate – The Vector Institute, Director – University of Toronto Temerty Centre for Artificial Intelligence Research and Education — Toronto, Ontario

Dr. Mamdani is Vice President of Data Science and Advanced Analytics at Unity Health Toronto and Director of the University of Toronto Temerty Faculty of Medicine Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM). Dr. Mamdani’s team bridges advanced analytics including machine learning with clinical and management decision making to improve patient outcomes and hospital efficiency. Dr. Mamdani is also Professor in the Department of Medicine of the Temerty Faculty of Medicine, the Leslie Dan Faculty of Pharmacy, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana Faculty of Public Health. He is also adjunct Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) and a Faculty Affiliate of the Vector Institute. In 2010, Dr. Mamdani was named among Canada’s Top 40 under 40. He has published over 500 studies in peer-reviewed medical journals. Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) and completed a fellowship in pharmacoeconomic and outcomes research at the Detroit Medical Center. During his fellowship, Dr. Mamdani obtained a Master of Arts degree in Economics from Wayne State University in Detroit, Michigan with a concentration in econometric theory. He then completed a Master of Public Health degree from Harvard University with a concentration in quantitative methods.

Dr. Muhammad Mamdani
, Toronto, Ontario

Presentation Summary

While the application of artificial intelligence (AI) has transformed numerous sectors including retail, transportation, and hospitality, its application to healthcare has been relatively limited. Health AI research has increased exponentially as has the number of commercially available AI solutions. A recent survey indicates approximately 40% of healthcare leaders are already using AI at their institutions. This session will review the concept of AI, its applications in healthcare, challenges in developing and deploying AI solutions in healthcare, and what future healthcare users of AI technologies should know when acquiring and/or using these exciting solutions.

Learning Objectives

  1. To provide a general overview of artificial intelligence and its implications for the diagnosis and management of cancer patients
  2. To discuss the barriers to implementation of artificial intelligence in clinical practice
  3. To provide a view of how artificial intelligence will transform healthcare with examples of its emerging role in the diagnosis and management of cancer patients
Registration
Registration Open
Break
Breakfast Amongst the Exhibits and Posters
Plenary session
Welcome Remarks
Plenary session
The Power of Maximizing Engagement and Energy to Avoid Burnout
Presenters
Dr. Karyn Gordon
Photo of Dr. Karyn Gordon
Photo of Dr. Karyn Gordon
Dr. Karyn Gordon
Leadership and Relationship Expert

Dr. Karyn Gordon’s purpose is to develop great leaders who drive success both at home and work. A bestselling author, top TEDx speaker, and media personality, Gordon has delivered over 1000 keynotes to more than half a million people across 17 countries — including Fortune 500 companies, entrepreneurs, and government agencies. She draws on her extensive research into leadership, relationships, and emotional intelligence to help audiences foster the skills needed to lead in the 21st century. 

Gordon is currently the founder and CEO of DK Leadership, a global leadership coaching company specializing in emotional intelligence skills for organizations and families. Known for her expertise, Gordon is often featured in national media outlets and is currently the leadership and relationship expert on Canada’s #1 daytime show, Cityline. She has previously worked with Good Morning America, Forbes, and The New York Times. Gordon is also a bestselling author with her most recent book, The Three Chairs: How Great Leaders Drive Their Teams’ Communication, Productivity, and Engagement, becoming a Wall Street Journal, USA Today, and Amazon bestseller.

A dynamic speaker, Gordon’s most recent TEDx talk “Why Confidence is the Secret to Great Leaders at Work and Home” is currently one of the top 40 most popular TEDx talks in 2022. She excels at communicating complex research in a simple and passionate way, and specializes in building effective multi-generational workforces and increasing engagement, productivity, and retention. Her past clients have included Pepsi, Credit Union, Young Presidents Organization, Entrepreneur Organization, PricewaterhouseCoopers, Canadian Tax Foundation, Ontario Family Judges, the University of Alberta, and the Government of Alberta.

Gordon has a bachelor’s in psychology, a master’s in counseling, and a doctorate in marriage and family. She has also completed several specialty leadership certifications with extensive research into generational differences, leadership, and emotional intelligence.

Dr. Karyn Gordon
Break
Refreshment Break amongst the Exhibits and Posters
Plenary session
Current Controversies in Evaluation of Renal Function in Oncology Practice
Presenters
Scott Edwards
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — St John's, Newfoundland and Labrador
Scott Edwards is currently the Clinical Oncology Pharmacy Specialist at the Dr. H. Bliss Murphy Cancer Center in St. John’s, Newfoundland. He is also an assistant professor at the School of Pharmacy and the Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland. He is active in clinical cancer research in the area of chemotherapy toxicities, supportive care and oral chemotherapy adherence. He graduated from Memorial University of Newfoundland with a B.Sc. (Neuroscience) in 1994 and a B.Sc (Pharmacy) in 1997. In 2005, he graduated with a Doctor of Pharmacy degree from the University of Washington. He completed a Master’s degree in Oncology from Newcastle University in 2015.
Scott Edwards
Eastern Health, St John's, Newfoundland and Labrador

Presentation Summary: 

There are many available methods to assess renal function in clinical practice.  In oncology, there are many inconsistencies in assessing renal function and no clear consensus in Canada on which method to assess renal function is preferred. This presentation will examine the evidence for the different methods to assess renal function in oncology patients. This presentation will evaluate, with patient cases, the impact of the different methods of assessing renal function on the initiation of oncology drugs and dosing adjustments for renal impairment. The presentation will also focus on the role of the oncology pharmacist in developing a standardized approach to assessing renal function in cancer patients. 

Learning Objectives:

  1. Describe the current methods for assessing renal function in cancer patients
  2. Discuss the evidence for newer methods of assessing renal function
  3. Determine the impact of the different methods of assessing renal function on oncology patient cases
CAPhO Annual General Meeting
Break
Networking Lunch amongst the Exhibits and Posters
Plenary session
Dose Banding in Oncology Practice
Presenters
Calum Polwart
Photo of Calum Polwart
Photo of Calum Polwart
Calum Polwart
Specialist Pharmacist Oncology , South Tees NHS Foundation Trust & Cancer Commissioning Pharmacist at NHSE/I (North East region) — International

Calum Polwart has been working in oncology pharmacy for more than 20 years. He has undertaken a number of roles within the North of England to provide world class oncology pharmacy services.  He is a non-medical prescriber working in a variety of solid tumours including Breast and GI cancers.  He recently accredited with the Royal Pharmaceutical Society as a Consultant Pharmacist. 

A self-confessed ‘geek’  he spends more time working with data in a week than “normal” people should in a lifetime! Despite that he still hasn’t been awarded a nobel prize. Polwart first implemented Dose Banding in his trust not long after the turn of the millennium, undertook work subsequent to this on making logarithmic dose banding more palatable to pharmacists and was seconded to the NHS England National Dose Standardisation Project to find a single national solution for dose banding in England. 

Calum Polwart
South Tees NHS Foundation Trust & Cancer Commissioning Pharmacist at NHSE/I (North East region), International
Concurrent session
Everything You Need to Know about PARP Inhibitors: Place in Therapy, Clinical Pharmacology, and Pharmaceutical Care
Presenters
Christine Peragine
Photo of Christine Peragine
Photo of Christine Peragine
Christine Peragine
Lead Pharmacist, Oral Anticancer Medication Program, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Dr. Christine Peragine is the Lead Pharmacist for Sunnybrook’s Oral Anticancer Medication (OAM) Program at the Odette Cancer Centre, Toronto, Ontario, Canada. Christine graduated from the University of Toronto combined BScPhm-PharmD program in 2015 and started her PhD training and Antimicrobial Stewardship-Infectious Disease Pharmacy Fellowship in the same year. She has worked in Ambulatory Oncology since 2018 and is passionate about advancing pharmacy practice, research, and education. Over the course of her career, Dr. Peragine has spearheaded over 25 practice-based research initiatives, published over 30 unique abstracts, and presented at over 15 academic conferences. She has received over $110,000 CAD in grant funding and was the recipient of the 2022 Sunnybrook Practice-Based Research and Innovation Award of Inquiry. Her commitment to teaching is demonstrated by the number of students and trainees she has precepted (>30), and the creation and launch of clinical and research co-op opportunities with the OAM Team in Fall 2022.
Christine Peragine
Sunnybrook Health Sciences Centre, Toronto, Ontario

Presentation Summary: 

This presentation focusses on the Poly ADP-Ribose Polymerase inhibitors (PARPIs) available in Canada. PARPI structure, biochemistry, indications, landmark trials, access, pharmaceutics, clinical pharmacology, toxicities and medication management will be discussed. 

Learning Objectives: 

By the end of this session, the learner will be able to: 

  1. Identify the PARPIs on the Canadian market and describe their mechanism of action 
  2. Describe PARPI indications & review key data from landmark clinical trials 
  3. Compare and contrast PARPI access and clinical pharmacology 
  4. Compare and contrast PARPI toxicities and monitoring strategies
Bay
Concurrent session
Precision Medicine and Fluoropyrimidine Dosing: The Evidence for Prospective DPYD Prescreening
Presenters
Carlo DeAngelis
Photo of Carlo DeAngelis
Photo of Carlo DeAngelis
Carlo DeAngelis
RPh, BScPhm, PharmD
Clinician Scientist, Pharmacy, Sunnybrook Odette Cancer Centre — Ancaster, Ontario
Carlo earned his BScPhm (1981) from the University of Toronto, a Hospital Pharmacy Residency (1982) at Sunnybrook Health Sciences Centre and a PharmD (1984) from the State University of New York at Buffalo. Carlo is the Oncology Pharmacy Clinician Scientist at the Sunnybrook Odette Cancer Centre (SOCC). He is an Assistant Professor at the Leslie Dan Faculty of Pharmacy. His research interests include, the role of the pharmacist in prevention and management of cancer treatment related side effects. Carlo leads a Cannabinoid Consultation Service at SOCC to meet the needs of cancer patients interested in using plant derived cannabinoids.
Carlo DeAngelis
Sunnybrook Odette Cancer Centre, Ancaster, Ontario

Presentation Summary: 

Fluoropyrimidines (FPs) continue to play a significant role in cancer therapeutics. They are used across the disease spectrum as single agents and in combination with other antineoplastics or radiation.
Their adverse effects (AEs) are well known. However, predicting AE occurrence and severity is challenging. Dihydropyrimidine dehydrogenase (DPD) is responsible for 5-FU metabolism. Patients with DPD-deficiency (coded by the DPYD gene) have increased susceptibility to FP AEs. The presentation will review the following aspects of prescreening for DPYD variants:
DPYD variants of clinical significance, data to support prescreening, Clinical Pharmacogenetics Implementation Consortium dosing guidelines, implementation challenges and the pharmacist’s role.

Learning Objectives: 
At the end of the presentation the Attendees will be able to:

 

  1. Describe the role of DPYD gene variants in the occurrence and severity of fluoropyrimidine adverse effects
  2. Recall the literature supporting prescreening for DPYD gene variants
  3. Explain the benefits of prescreening for DPYD gene variants
  4. Identify resources to aid in fluoropyrimidine dosing based on DPYD gene variant prescreening results
  5. Recall the enablers and challenges to implementing prescreening of DPYD gene variants
Concurrent session
Innovations in Pharmacy – Implementing a Mobile Mixing Trailer to Support Pharmacy Renovations
Presenters
Jennifer Suess
Photo of Jennifer Suess
Photo of Jennifer Suess
Jennifer Suess
BSc (Pharm)
Pharmacy Professional Practice Leader, BC Cancer — Abbotsford, British Columbia

Jennifer Suess received her BSc (Pharm) from the University of Manitoba.  She has worked as a Clinical Pharmacist in a variety of inpatient and outpatient settings across British Columbia and Alberta before transitioning into her current role as the Pharmacy Professional Practice Leader at the BC Cancer - Abbotsford Centre.  Highlights of her career include spearheading the implementation of a pharmacist within the ambulatory care team at BC Cancer, creating emergency plans to support patients on oral treatments during the 2021 Abbotsford floods, and successfully implementing a unique mobile mixing trailer to support NAPRA renovations.

Jennifer Suess
BC Cancer , Abbotsford, British Columbia

Presentation Summary:


If innovations are the creative by-product of challenges then hospital pharmacy renovations should provide the perfect conditions for generating innovative ideas.  Join us to hear how the BC Cancer used a Mobile Mixing Trailer to maintain hazardous drug compounding services during recent NAPRA renovations.

Learning Objectives:

  • To describe the innovative implementation of a mobile mixing trailer to enable continuity of care during pharmacy renovations
  • To describe the process of complying with NAPRA standards within a mobile mixing trailer
Concurrent session
Global Pharmacy: Experience Pearls from Vancouver to Kathmandu and Places in between
Presenters
Fatima Ladha
Photo of Fatima Ladha
Photo of Fatima Ladha
Fatima Ladha
B.Sc (Pharm)
Provincial Pharmacy Education and Residency Program Coordinator, BC Cancer

Dr. Fatima Ladha holds a B.Sc (Pharm) from UBC, a certificate from UBC Community Pharmacy Practice Residency Program, and a PharmD from the University of Toronto. She worked for Fraser Health as a clinical pharmacist, focusing her practice in oncology and palliative care. In 2019, Fatima joined BC Cancer.  Her current role is the Provincial Pharmacy Education and Residency Program Coordinator.  Fatima is a clinical instructor with the Faculty of Pharmaceutical Sciences at UBC. She also volunteers with Two Worlds Cancer Collaboration supporting clinical training, collaboration, and mentorship of healthcare providers in South and Southeast Asia.

Fatima Ladha
BC Cancer

Presentation Summary: 

There are two worlds of healthcare.  In regions of South and Southeast Asia, 80% of young people diagnosed with cancer and other serious illnesses die.  In countries such as Canada, approximately 80% of young people with similar diagnoses will survive.  There are opportunities to harness Canadian and international healthcare knowledge and leadership to assist healthcare providers in lesser-resourced countries. Through education and mentorship collaborations, we can close the circle and reduce the burden of cancer and other life-limiting illnesses. As drug therapy specialists, pharmacists’ clinical expertise remain under-utilized within healthcare teams that serve patients in low and middle income countries (LMIC).  How can we change that?

Learning Objectives: 

By the end of this session, I hope to share my experiences so attendees can: 

  1. Realize the perceptions of pharmacists in Lower Middle Income Countries (LMICs).
  2. Appreciate how pharmacists can integrate within global teams that collaborate creating capacity for LMICs.  
  3. Optimize education initiatives and advocacy for inclusion of clinical pharmacy practice in LMICs.
Break
Refreshment Break amongst the Exhibits and Posters
Concurrent session
Cholangiocarcinoma – A Primer and Overview of Management
Presenters
Mark Pasetka
Photo of Mark Pasetka
Photo of Mark Pasetka
Mark Pasetka
Oncology Pharmacy - Clinical Practice Lead, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Since completing his BScPharm in 2004 (UManitoba), PharmD (UToronto) in 2009, and clinical and research fellowship in oncology at Sunnybrook Health Sciences Centre in 2011, Mark has been serving as the Oncology Pharmacy Clinical Practice Lead at the Odette Cancer Centre. Areas of practice include supportive care and is a member of the gastrointestinal cancer site group. In addition to clinical care, Mark has a strong interest in patient and health professional education. Along with the pharmacist team, he has precepted pharmacy trainees of all levels continuously since 2012. Mark also is the current Year One Pharmacy Residency Coordinator.
Mark Pasetka
Sunnybrook Health Sciences Centre, Toronto, Ontario

Presentation Summary: 

Since completing his BScPharm in 2004 (UManitoba), PharmD (UToronto) in 2009, and clinical and research fellowship in oncology at Sunnybrook Health Sciences Centre in 2011, Mark has been serving as the Oncology Pharmacy Clinical Practice Lead at the Odette Cancer Centre.  Areas of practice include supportive care and is a member of the gastrointestinal cancer site group.  In addition to clinical care, Mark has a strong interest in patient and health professional education.  Along with the pharmacist team, he has precepted pharmacy trainees of all levels continuously since 2012.  Mark also is the current Year One Pharmacy Residency Coordinator.  

Learning Objectives:

  1. Summarize the pathophysiology, risk factors, and incidence of cholangiocarcinoma
  2. List the current systemic treatments for management of cholangiocarcinomas
  3. Describe the supportive care management of patients receiving systemic therapy
Bay
Concurrent session
Technician Panel: BPMH Responsibilities
Presenters
Amanda Trigiani
Randi Coons
Amanda Trigiani
Pharmacy Technician Team Lead, Stronach Regional Cancer Centre, Southlake Regional Health Centre — Newmarket, Ontario

Amanda graduated in 2005 from the Pharmacy Technician program at Niagara College in Welland, ON. With over 10 years experience, Amanda has accumulated a wealth of knowledge and unique skills that have helped shape her career as a Registered Pharmacy Technician. Amanda started working at Southlake Regional Health Centre in 2010. She transitioned to Oncology Pharmacy in 2017 and has held the Pharmacy Technician Team Lead and Compounding Supervisor titles at Stronach Regional Cancer Centre since 2018. In June 2022, Amanda completed her Masters Certificate in Healthcare Management.

Amanda Trigiani
Southlake Regional Health Centre, Newmarket, Ontario
Photo of Randi Coons
Photo of Randi Coons
Randi Coons
RPhT
Pharmacy Technician, Pharmacy, Saskatchewan Cancer Agency — Regina, Saskatchewan
Randi completed her Pharmacy Technician Certificate at SIAST (now Saskatchewan Polytechnic) in Saskatoon, SK in 2014. She has experience in both hospital and retail pharmacy settings, and has also worked as an assessor for the Pharmacy Examining Board of Canada for both the technician OSPE examinations and in the development of a Portfolio Assessment program for international graduates. Randi has worked for the Saskatchewan Cancer Agency since 2018 and currently works as the Pharmacy Technician Site Lead at the Allan Blair Cancer Centre in Regina. She also holds a position with Saskatchewan Polytechnic as the instructor of the Structured Practical Training Assessment course.
Randi Coons
Saskatchewan Cancer Agency, Regina, Saskatchewan

Presentation Summary: 

A review of best practices when completing BPMH and the roles technicians have in these processes. Discussion of the ideal staffing levels to be able to perform BPMH for all patients and any special considerations when performing a BPMH in an oncology setting.

Learning Objectives: 

By the end of this panel, participants will:

  1. After participating in this panel, attendees will be able to define a BPMH and describe the role of pharmacy technicians within that definition. 
  2. Throughout the panel, participants will identify special considerations for BPMH’s performed in an oncology setting.
  3. By the end of this panel, participants will understand what the staffing requirements are for optimal BPMH collection.
Concurrent session
Investigation and Remediation of Excursions in HD Compounding Environments
Presenters
Melanie Dorey
Photo of Melanie Dorey
Photo of Melanie Dorey
Melanie Dorey
CEO & Consultant, Critical Compounding Resources
Melanie Dorey
Critical Compounding Resources

Presentation Summary: 

Since hazardous drug cleanrooms are a negative pressure environment they tend to cause challenges with excursions during environmental monitoring. There are many aspects that may contribute to these excursions and this lecture will help identify some of those causes but also bring forward suggestions for remediation. Running a thorough, documented investigation and remediation is key in order to prevent a failure in contamination control. 

Learning Objectives: 

  1. Determine the NAPRA Model Standard requirements for environmental monitoring, investigation, and remediation. Discuss common issues found with environmental monitoring in negative pressure cleanrooms.
  2. Explain key components for investigation and remediation of environmental excursions.
  3. Provide suggestions for investigation and remediation strategies.
  4. List documentation elements recommended for an investigation and remediation. 
Concurrent session
Acute Myeloid Leukemia 101: a Changing Landscape for Community Pharmacists
Presenters
Joy Rashid
Photo of Joy Rashid
Photo of Joy Rashid
Joy Rashid

Joy is a graduate of the University of Manitoba BSc. Pharmacy program in 2011 after which she worked at the St. Boniface Hospital in Winnipeg for two years. She completed a hospital residency program at The Ottawa Hospital in 2014 and has worked there since then, specializing in inpatient malignant hematology. Most recently, Joy has shifted to a primarily outpatient-based practice in her role as a Hematology Program Coordinator at Extend Pharmacy, an oncology focused community pharmacy. She has taken on roles as a pharmacy preceptor, OSCE assessor, past member of the CAPhO Education Committee, contributed to research residency projects and participated in an international mission/preceptorship with Pharmacists Without Borders. 

Joy Rashid

Presentation Summary: 

Acute Myeloid Leukemia (AML) is the most common leukemia in adults, however until recently, the treatment toolbox for these patients was limited. Over the last several years, the landscape has changed significantly with the availability of novel targeted agents and oral therapies. With this evolution, comes a greater role for community pharmacists to participate in the care of the AML patient population. This presentation will provide a foundation for understanding the evolution of AML treatments, basic treatment principles and the key roles of the community pharmacist in the care of these patients.

Learning Objectives:

  1. Contrast the goals of AML treatment: curative vs palliative
  2. Summarize the evolution of AML treatment over the years
  3. Identify novel and targeted agents for the treatment of AML and their place in therapy 
  4. Apply the key roles of the pharmacist to your practice:
  • Recognize common side effects of treatment and associated supportive care medications
  • Provide patient education for select common side effects
Yoga Session
Running Group
Awards Gala and Entertainment

Sunday
April 16, 2023
Program is subject to change. All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Gilead Sponsored Symposium- Redefining the Lines of Triple-Negative Breast Cancer
Presenters
Scott Edwards
Benny Romano
Dr. Sandeep Sehdev
Glenn Myers
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — St John's, Newfoundland and Labrador
Scott Edwards is currently the Clinical Oncology Pharmacy Specialist at the Dr. H. Bliss Murphy Cancer Center in St. John’s, Newfoundland. He is also an assistant professor at the School of Pharmacy and the Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland. He is active in clinical cancer research in the area of chemotherapy toxicities, supportive care and oral chemotherapy adherence. He graduated from Memorial University of Newfoundland with a B.Sc. (Neuroscience) in 1994 and a B.Sc (Pharmacy) in 1997. In 2005, he graduated with a Doctor of Pharmacy degree from the University of Washington. He completed a Master’s degree in Oncology from Newcastle University in 2015.
Scott Edwards
Eastern Health, St John's, Newfoundland and Labrador
Photo of Benny Romano
Photo of Benny Romano
Benny Romano
RN, BScN, CON(C)
Pivot Nurse in Oncology, St. Mary's Hospital, Cancer Care Clinic — Montreal, Quebec

Benny Romano is currently working at St. Mary’s Hospital in Montreal Quebec.  With 20 years of experience in the oncology department, she has worked both in the in-patient unit and the ambulatory setting, where she is currently assigned as the pivot nurse in oncology since 2014.
Benny manages the cases of newly diagnosed patients, including breast cancer, and she helps them navigate through their cancer journey.  
She graduated with a collage degree in Nursing at Dawson College in Montreal, Quebec, then pursued her studies and graduated with honors in B. Sc. In Nursing from the University of Ottawa in 2010.  She later obtained her certification in oncology in 2018.

Benny Romano
St. Mary's Hospital, Cancer Care Clinic , Montreal, Quebec
Photo of Dr. Sandeep Sehdev
Photo of Dr. Sandeep Sehdev
Dr. Sandeep Sehdev
Medical Oncologist, The Ottawa Hospital Cancer Centre — Ottawa, Ontario

Sandy Sehdev trained in medical oncology at the University of Toronto and The Princess Margaret Cancer Centre (1991).  

He worked at The William Osler Health System (Toronto) for 25 years (-2016) and while there was Chief of the Pharmacy & Therapeutics Committee, and lead of the clinical trials program (oncology) and continuing medical education (oncology). He was a past lead of CME for the Community Oncologists of Metropolitan Toronto (COMET), and a past Director of the Cancer Advocacy Coalition of Canada.  He is a co-founder of the Physician Alliance for Cancer Care and Treatment (Canada), an oncologist led advocacy coalition, and is a scientific advisor for the Canadian Cancer Survivor Network, and the Canadian Breast Cancer Network. 

He is currently a medical oncologist at The Ottawa Hospital Cancer Centre, focusing on the treatment of breast, prostate cancers and melanoma and lead for the breast cancer disease site.  He was the 2020 winner of the “Golden Throat” teaching award.  
 

Dr. Sandeep Sehdev
The Ottawa Hospital Cancer Centre, Ottawa, Ontario
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
Pharmacist with clinical focus in outpatient medical oncology, Dr. Sheldon H Rubin Oncology Clinic — Moncton, New Brunswick

Glenn Myers completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy. 

Glenn Myers
Dr. Sheldon H Rubin Oncology Clinic, Moncton, New Brunswick

Presentation Summary:

Join Dr. Sandeep Sehdev, Scott Edwards, Glenn Myers and Benedict Romano for an interactive discussion entitled ‘Redefining the Lines of Triple-Negative Breast Cancer’.  In addition to an update on the current and emergent therapies, the panel in this Symposium will focus on exchanging practical experiences and tips with patient management.  

Learning objectives

  1. Review the TNBC treatment landscape 
  2. Discuss the evidence of new therapies for metastatic TNBC
  3. Learn real-life tips for managing adverse events using patient cases
Registration
Registration Open
CAPhO Town Hall Breakfast Meeting
CAPhO Poster Award Presentations
Plenary session
Medication Assessment by Pharmacist (MAP) Program
Presenters
Elaine Goh
Photo of Elaine Goh
Photo of Elaine Goh
Elaine Goh
Clinical Pharmacist, BC Cancer Surrey — Surrey, British Columbia

Elaine Goh is a board certified oncology pharmacist and clinical pharmacist at BC Cancer in Surrey, BC. She received her Bachelor of Science in Pharmacy degree from the University of British Columbia. Elaine started working in oncology in 2008. In her current role at BC Cancer Surrey, she coordinates the clinical activities of the ambulatory clinic oncology pharmacists. She is passionate about developing programs and initiatives that allow oncology pharmacists to expand their clinical roles, while optimizing patient care and health care delivery in the ambulatory oncology setting.  Elaine is honoured to be the recipient of the CAPhO 2023 Merit Award in recognition of the Medication Assessment by Pharmacist (MAP) program.

Elaine Goh
BC Cancer Surrey, Surrey, British Columbia

Presentation Summary: 

The Medication Assessment by Pharmacist (MAP) program is a shared care model between medical oncologists and pharmacists at BC Cancer Surrey. MAP started in February 2019 in breast cancer patients on CDK4/6 inhibitors, but has expanded to encompass multiple oral oncology drugs. In this program, stable patients deemed suitable by their oncologist can alternate seeing oncologist and pharmacist at every other clinic visit. This reduces ambulatory patient visits for oncologists, allowing them to see other patients or complicated cases. MAP may help alleviate oncology provider shortages, and creates an opportunity for pharmacists to expand clinical roles in direct patient care. 

Learning Objectives:

  1. Describe the Medication Assessment by Pharmacist (MAP) program 
  2. Recognize some of the drugs and malignancies covered in the MAP program
  3. List the key steps in establishing and implementing the program, and describe some of the possible challenges
  4. Discuss potential future directions of the program
Break
Refreshment Break in the Foyer
Plenary session
NIOSH Categorization of HDs: ON and BC Approaches
Presenters
Andrew Wyllie
Nadine Badry
Photo of Andrew Wyllie
Photo of Andrew Wyllie
Andrew Wyllie
Senior Manager, Quality and Academic Practice, Department of Pharmacy Services, Sinai Health — Toronto, Ontario

Andrew Wyllie is the senior manager of quality and academic practice at Sinai Health.  He has a BScPhm and PharmD from UofT, and a residency from London Health Sciences Centre.  He recently completed a quality scholars fellowship with US Veterans Affairs.

Andrew has been working with a group of gifted colleagues in the Toronto area to draft a guidance document on hazardous drugs which will be used to standardize hazardous drug lists and the precautions taken with hazardous drugs. 

Andrew’s life is balanced out with fun and relaxation with his brainiac wife, kids and spirited goldendoodle Willow.

Andrew Wyllie
Sinai Health, Toronto, Ontario
Photo of Nadine Badry
Photo of Nadine Badry
Nadine Badry
Pharmacist, Pharmacy, BC Cancer — Victoria, British Columbia
Nadine Badry is the Editor of the Cancer Drug Manual at BC Cancer. She received her Bachelor of Science degree in Pharmacy from the University of Alberta in 1986 and completed her hospital pharmacy residency at the Ottawa Civic Hospital in 1987. Nadine has worked in different community and hospital practice settings in Alberta, Ontario, and British Columbia and she has worked for BC Cancer since 2005. Nadine’s strong interest in promoting the identification and safe handling of hazardous drugs has afforded her several opportunities to serve on internal and provincial working groups for the prevention of occupational exposure to drugs.
Nadine Badry
BC Cancer, Victoria, British Columbia

Presentation Summary: 

Any healthcare professional working in a setting where hazardous drugs are transported, prepared, administered to patients, or handled for disposal may be directly or indirectly exposed to hazardous drugs through the course of their work. Occupational exposure is typically defined as the chronic low-dose exposure that occurs when hazardous drugs are handled over the course of a career, but may also include acute exposures to drug spills and body fluids. Health risk depends on the degree of exposure over time and the inherent toxicity of the applicable drugs. Efforts to minimize occupational exposure should include the identification of drugs which are hazardous and the implementation of safe handling standards for hazardous drugs used in different healthcare settings. Two organizations will describe their approach to hazardous drugs.

Learning Objectives: 

At the conclusion of this activity, participants will be able to:

  1. Describe two different provincial approaches to the development and maintenance of an institutional hazardous drug list
  2. Identify the advantages and challenges of adopting the NIOSH 2020 Draft List of Hazardous Drugs for the creation/maintenance of an institutional hazardous drug list
  3. Discuss some options for disseminating information about hazardous drugs to other allied health professionals within their institution
Round table discussion
6. Practical Aspects of CDK 4/6 Inhibition
Presenters
Tom McFarlane
Tom McFarlane
Tom McFarlane

This round table will discuss the management of adverse effects and drug interactions with CDK 4/6 inhibitors, particularly as they start to enter the adjuvant treatment space.

Round table discussion
8. Drug Access Workload and Inventory Management
Presenters
Steven Riddick
Steven Riddick
Steven Riddick

Steven will discuss the increasing use of compassionate drug supplied to our center and strategies we use to keep on top of reordering. Also, the time and effort that goes into private infusion clinic coordination and how to keep organized in this role in general.

Round table discussion
5. Climate Change - On the Front Line of the Oncology Pharmacy Profession
Presenters
Shellyza Moledina Sajwani
Photo of Shellyza Moledina Sajwani
Photo of Shellyza Moledina Sajwani
Shellyza Moledina Sajwani

Shellyza Sajwani is a pharmacist who works within areas of oncology, global health and climate change as they relate to the pharmacy profession. She is the national co-chair of the new Canadian Association of Pharmacy for the Environment (CAPhE), and also works with the International Federation of Pharmacists as the co-chair of their environmental sustainability policy committee. She is also the co-chair of the Ottawa Hospital Pharmacy Environmental Committee, and has experience working as the previous co-president of Pharmacists Without Borders Canada and as an oncology pharmacy consultant in Gulu, Uganda in 2017 and 2018. Shellyza currently works as an oncology pharmacist at the Ottawa Hospital, with eight years of experience in a combination of outpatient and inpatient oncology. She is an ovarian cancer survivor, and has worked with organizations such as Young Adult Cancer Canada and Ovarian Cancer Canada in advocating for cancer patients.  

Shellyza Moledina Sajwani

Climate change is impacting oncology in multiple ways - through the impact to cancers and comorbidities themselves, through the impact to medication management as well as through access to treatment. This session will provide a brief introduction to all three areas, and provide a greater understanding of the oncology pharmacist role in climate change and planetary health more generally. 

Round table discussion
4. Development and Implementation of a Hazardous Drug Wipe Sampling Program
Presenters
Michelle Koberinski
Michelle Koberinski
Michelle Koberinski

Contamination of work areas with hazardous drugs poses a health risk to healthcare workers. Surface wipe sampling measures levels of hazardous drug contamination allowing employers to assess risk levels and take appropriate action.

Round table discussion
3. Outpatient Prevention and Management of Febrile Neutropenia: Updates to Ontario’s Guidelines
Presenters
Kathy Vu
Kathy Vu
Kathy Vu

This session will focus on what’s new in the updated recommendations for the prevention of febrile neutropenia (FN) and new guidelines for the outpatient management of FN in adult cancer patients receiving systemic treatment in Ontario.  Share best practices among different institutions on the assessment for outpatient management as well as prevention and management of FN.

Round table discussion
1. Choose Your Adventure or Pick Your Poison: Psychedelics, Medicinal CBD, Opioid Switching, or Opioid-Induced Constipation in Palliative Care
Presenters
Chris Ralph
Chris Ralph
Chris Ralph

In this round table discussion, participants choose which topic in the realm of palliative care they would like to focus on. From the reemergence of therapeutic psychedelics, the potential drug interactions with these agents, to looking at a recent study on CBD use in advanced cancer patients, to a novel way to consider when opioid switching, to opioid-induced constipation management tips, we can rethink these topics that have been around for decades.

Round table discussion
2. Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment
Presenters
Christine Piescic
Christine Piescic
Christine Piescic

Discussion around the OH-CCO Hepatitis B Virus Screening and Management Guidelines for patients receiving systemic treatment and implementation at a mid-sized Regional Cancer Centre. 

Round table discussion
7. Chemo Induced Hair Loss and the Cold Cap Experience
Presenters
Natalie Cabral
Mova Leung
Natalie Cabral
Natalie Cabral
Mova Leung
Mova Leung

Natalie will be sharing her experience with the Paxman cold cap system while she was on chemotherapy.  Mova will briefly present the evidence and support for cold cap therapy.

Plenary session
Closing Remarks
Satellite symposium
Pfizer ULC Sponsored Symposium - Biosimilars in Oncology - Best Practices for Optimizing Care
Presenters
Scott Edwards
Lauren (Flay) Charbonneau
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — St John's, Newfoundland and Labrador
Scott Edwards is currently the Clinical Oncology Pharmacy Specialist at the Dr. H. Bliss Murphy Cancer Center in St. John’s, Newfoundland. He is also an assistant professor at the School of Pharmacy and the Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland. He is active in clinical cancer research in the area of chemotherapy toxicities, supportive care and oral chemotherapy adherence. He graduated from Memorial University of Newfoundland with a B.Sc. (Neuroscience) in 1994 and a B.Sc (Pharmacy) in 1997. In 2005, he graduated with a Doctor of Pharmacy degree from the University of Washington. He completed a Master’s degree in Oncology from Newcastle University in 2015.
Scott Edwards
Eastern Health, St John's, Newfoundland and Labrador
Photo of Lauren (Flay) Charbonneau
Photo of Lauren (Flay) Charbonneau
Lauren (Flay) Charbonneau
Manager, Pharmacy, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Long time CAPhO and CAPhO Conference organizing and sponsorship committee member. Member of ISOPP, and founding member of local Toronto oncology pharmacists’ group, OPTRA. Oncology pharmacy education is so important to what we do every day; it helps to inspire new and seasoned practitioners to make a difference for their patients.
Lauren (Flay) Charbonneau
Sunnybrook Health Sciences Centre, Toronto, Ontario

As more biosimilars become available in Canada, they present a significant opportunity to change the oncology treatment and supportive care landscape. However, it is essential that healthcare providers have a strong understanding of these products to ensure effective implementation into clinical practice. Join us for a review of biosimilar best practices within oncology, including a panel discussion around the practicalities of working together to optimize patient care.